<DOC>
	<DOCNO>NCT01669174</DOCNO>
	<brief_summary>This study ass pharmacodynamics , pharmacokinetics , safety tolerability BYM338 patient COPD cachexia . The primary outcome change thigh muscle volume compare placebo . The study last approximately 24 week .</brief_summary>
	<brief_title>BYM338 Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Cachexia</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antibodies , Blocking</mesh_term>
	<criteria>Inclusion criterion : Written inform consent must obtain assessment perform . Males female age 40 80 year Smoking history least 10 packyears Diagnosis COPD accord GOLD guideline ( GOLD , 2010 ) , postbronchodilator FEVÂ¬1 &lt; 80 % predict FEV1/FVC ratio &lt; 0.70 BMI &lt; 20 kg/m2 skeletal muscle mass index DXA &lt; 7.25 kg/m2 men &lt; 5.45 kg/m2 woman . In general stable health , include manage COPD , past medical history , physical examination , vital sign baseline determine investigator . Exclusion criterion : Patients MRC dyspnoea grade 5 ( i.e . patient breathless leave house breathless dress ) Plans lung transplantation lung reduction surgery within four month enrollment Patients participate formal pulmonary rehabilitation program within 3 month dose History malignancy organ system ( excise nonmelanomatous carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . Diseases cancer know cause cachexia muscle atrophy , include limited congestive heart failure stage , chronic kidney disease ( estimate GFR &lt; 30 mL/min use MDRD equation ) , rheumatoid arthritis , primary myopathy , stroke , HIV infection , tuberculosis chronic infection , uncontrolled diabetes mellitus , etc . Inflammatory bowel disease , celiac disease , short bowel syndrome , pancreatic insufficiency Use prescription drug know affect muscle mass , include androgen supplement , antiandrogens ( LHRH agonist ) , antiestrogens ( tamoxifen , etc . ) recombinant human growth hormone ( rhGH ) , insulin , oral beta agonist , megestrol acetate , dronabinol , metformin , etc . Hemoglobin concentration 11.0 g/dL screening . Liver disease liver injury . Use investigational drug time enrollment , within 30 day limitation participation investigational trial base local regulation . Women childbearing potential . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD ; cachexia ; muscle wasting</keyword>
</DOC>